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NPRL2/TUSC4 FUNCTIONS AS A TUMOR SUPPRESSOR BY REGULATING
BRCA1’S STABILITY VIA THE E3 UBIQUITINATION PATHWAY

Yang Peng, M.S
Supervisory Professor: Shiaw-Yih Lin, Ph.D

Expression of the tumor suppressor protein BRCA1 is frequently lost in breast
cancer patients, and the loss of its expression is associated with disruption of
various critical functions in cells and cancer development. In the present study,
we demonstrate through microarray analysis that cells with tumor suppressor
candidate 4 (NPRL2/TUSC4) knockdown show critical changes to cell cycle, cell
death pathways and a global impact on cancer development. More importantly,
we observed a clear cluster pattern of NPRL2/TUSC4-knockdown gene profiles
with established homologous recombination (HR) repair defect signature.
Additionally, NPRL2/TUSC4 protein physically interacts with the E3 ligase
HERC2

and

prevents

ubiquitin

pathway-mediated

BRCA1

degradation.

Knockdown of NPRL2/TUSC4 expression enhanced BRCA1 polyubiquitination,
leading to BRCA1 protein degradation and a marked reduction in HR repair
efficiency.

Conversely,

ectopic

expression

of

NPRL2/TUSC4

effectively

suppressed the proliferation, invasion, and colony formation of breast cancer
cells

in

vitro

and tumorigenesis

in vivo.

Furthermore, knockdown

of

NPRL2/TUSC4 expression transformed normal mammary epithelial cells and

v

enhanced the sensitivity of U2OS cells to the treatment of poly(ADP-ribose)
polymerase inhibitors. Therefore, NPRL2/TUSC4 may act as a bona fide tumor
suppressor by regulating BRCA1 protein stability and function in breast cancer.
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Chapter 1

INTRODUCTION AND BACKGROUND

BRCA1 maintains DNA damage response in breast cancer

Tumor suppressor and cancer development
According to Hanahan and Weinberg’s updated review in 2011, they redefined the six classical hallmarks of cancer development: sustaining proliferative
signaling, resisting cell death, inducing angiogenesis, enabling replicative
immortality, activating invasion and metastasis and evading growth suppressors
(Hanahan and Weinberg, 2011). This concept systematically and fundamentally
explains the most critical characteristics most cancer cells need to acquire during
their development.

However, it’s unlikely these abnormities would occur

synchronically and naturally under normal circumstances, instead it’s more likely
that the tumor proliferation is regulated sequentially, while any of these defects can
be raised. For example, sustaining proliferative signaling also requires cancer cells
disrupt the normal growth regulation mechanism, and lead to the evasion of cell
growth suppressors, but many of these processes are conducted by tumor
suppressor genes. Tumor suppressors operate in numerous ways to limit cell
growth and proliferation to prevent cancer. Genome-wide screening has shown
that many tumor suppressor genes are deleted or mutated in various types of
cancers, with the inactivation patterns of many well-recognized tumor suppressor
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genes being well characteristic and non-randomized (Vogelstein et al., 2013).
Recent studies also confirmed the mutation of certain tumor suppressor genes
confers to selective tumor growth advantages (Xue et,al., 2012).

BRCA1 and breast cancer
As the most diagnosed and leading cause of cancer-related deaths in women,
breast cancer is responsible for the 180,000 new cases in the United States alone
and 1.6 million worldwide, while more than a half million women died in 2011
primarily due to the lack of early detection (Global Health Estimate, WHO 2013).
Among those cancer patients, women with BRCA1 mutations are six times more
likely to develop cancer before the age of 70 compared to women with normal
BRCA1 (NCI, 2014). Thus to investigate the relationship between BRCA1 and
breast cancer as well as how BRCA1 is regulated before the early cancer lesions
posed extreme challenges and remarkable clinical potentials to current breast
cancer research fields.

DNA damage response and BRCA1
DNA damage can be caused by various sources, and leads to genomic
stress for the cell. To safeguard the integrity and fidelity of genomic information,
cells activate the evolutionary conserved DNA damage response pathways to
manage the lesions once the lesions are found. Cell cycle checkpoints will stop the
damaged cells from dividing and activate the damage repair mechanisms. If the
DNA damage lesion can be fixed, cell cycle will restart, otherwise, the cells will be
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eliminated by apoptosis pathway (also known as programmed cell death) (Medema
and Macurek, 2012). Depends on the damage types, different pathways are
responsible for the DNA double strand breaks (DSB) and DNA single-strand break
(SSB). Most current understanding indicate that Ataxia Telangiectasia Mutated
(ATM) and Ataxia Telangiectasia and Rad3-Related (ATR) are the main players in
mediating cells' DSB and SSB responses respectively, although the molecules
involved in each pathway can overlap (Ciccia and Elledge, 2010) (Figure 1). Upon
the recognition of DNA breaks by sensor proteins, ATM and ATR quickly undergo
the autophosphorylation or phosphorylation of their substrates, such as CHK1 and
CHK2 (Zhou and Elledge, 2000). Histone protein H2AX will rapidly get
phosphorylated at Ser-139 by ATM or ATR and produce γ-H2AX at the damage
sites, in turn recruit other damage repair proteins to the broken DNA. ATM and
ATR also phosphorylates their own unique substrates to stimulate DSB and SSB
responses respectively. More specifically, ATM phosphorylates checkpoint kinase
2 (CHK2) at Thr-68 and ATR phosphorylates checkpoint kinase 1 (CHK1) at Ser317 and Ser-345. CHK2 phosphorylation in turn leads to p53 phosphorylation,
MDC1, RNF8, RNF168, BRCA1 and 53BP1 recruitment to the damage sites while
CHK1 phosphorylation is followed by the phosphorylation of Cdc25A and Tlk1/2.
These processes induce downstream processes that includes damage-induced
transcription, DNA repair, cell cycle arrest/delay, apoptosis and chromatin
remodeling (Bartek and Lukas, 2003).
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BRCA1 safeguards genome integrity and regulates DNA damage repair
BRCA1 gene was first identified and cloned in 1994. BRCA1 protein
contains 1863 amino acids and located on chromosome 17q21. Its C-terminus has
BRCT motif to recognize and interact with various DNA repair proteins, while its Nterminus contains a ring-finger domains allowing proteins interactions such as
BRCA1-associated RING domain-1 protein (BARD1) to form heterodimer, and this
complex was confirmed to carry ubiquitination ligase activities (Xia et al., 2003).
BRCA1 plays multiple roles to regulate normal molecular and cellular functions
such as cell cycle checkpoint control, mRNA transcription regulation and DNA
damage repair (Kennedy et al, 2004)(Figure 3). Loss-of-function mutation for
BRCA1 correlates with approximately 82% risk of developing breast cancer (King
et al., 2002) (Figure 2) and low BRCA1 expression is associated with significant
increase of sporadic cancer incidences (Couch et al., 1997; Wang et al., 2004).
There are two major DNA damage repair mechanisms involve in mammalian
cells, homologous recombination (HR) repair and non-homologous end joining
repair. Previous reports indicated that BCRA1 play important roles in both repair
pathways and it involves intensively in HR repair to protect cells to repair DNA
double-strand break (DSB) in a least error-prone manner (Figure 4).

Role of BRCA1 in homologous recombination (HR) repair
HR repair has been considered as one of the most important mechanism to
maintain genomic stability during DSB by mediating error-free repair (Levitt and
Hickson 2002). The deficiency of HR repair is associated with cancer development
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and sensitize DNA damage-inducing therapy (Alli et al., 2009). When DNA DSB
occurs, HR repairs DNA during the S and G2 phases and before M phase of cell
cycle. After cell sensing the DSB, BRCA1 will be recruited and form protein
complex with Rad50, MRE11 and NBS1 (also known as MRN complex), the
BRCA1-MRN complex can take 5’—3’ exonuclease activity and expose 3’ end of
the break DNA, either single-strand annealing or strand invasion will occur during
the process of repair (Karran 2000). It is believed that BRCA1 participates in the
strand invasion repair system and also physically interact with BRCA2, RAD51 to
form repair complex at the DNA damage break sites (Karran 2000; Gilmore et al.,
2003), based on the earliest evidence from the previous reports that BRCA1
deficient in stem cells leads in the increased sensitivity to alkylating reagents which
commonly used to cause DNA DSB (Moynahan et al., 2001). Recent works
supported this statement that mutation or inactivation of BRCA1 will not only impair
HR repair efficiency but also decrease the accuracy of NEHJ repair pathway and
eventually enlarge the effect of DNA damage toxicity and increase the possibility of
early cancer lesions.

Role of BRCA1 in cell cycle regulation and drug sensitivity
BRCA1 has been reported to be a cell cycle regulator majorly owing to its role
as the substrate of DNA damage kinases such as ATM and ATR, and Checkpoint
Kinase 2 (CHK2) (Yarden et al., 2002; Xu et al., 2001; Xu et al., 2002). ATM and
ATR mainly respond to DNA double strand breaks such as ionizing irradiation and
DNA single strand breaks such as Ultraviolet respectively (Zou and Elledge 2003).
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BRCA1 can be phosphorylated by ATM, ATR and CHK2 at various sites, and in
turn activate the checkpoint of cell cycle (Cortez et al., 1999; Lee et al., 2000;
Tibbetts et al., 2000). It has been suggested that phosphorylated BRCA1 is
associated with transcriptional activation of multiple critical checkpoint proteins and
stimulate their expression level such as p21, p27 in G1/S phase arrest by inhibiting
cyclin-depedent kinase 2(CDK2), but mechanism of how BRCA1 is involved in cell
cycle checkpoint remains unclear (Somasundaram et al., 1997).
Additionally, mouse embryonic fibroblast with mutated BRCA1 showed
increased DNA damage causing drugs’ sensitivity such as Irinotecan and
Etoposide which target DNA topoisomerase I and II respectively (Fedlier et al.,
2003). Accumulating evidence indicated BRCA1 is important in the inhibition of cell
apoptosis after the treatment of DNA-damaging drugs, especially in breast cancer
cell lines (Kennedy et al., 2004). Thus, the disruption of BRCA1 will significantly
decrease cell’s capacity to fix both double-strand break caused by drugs such as
Irinotecan, Etoposide, as well as PARP inhibitors, and such increased drug
sensitivity in cell is largely owing to their impaired capacity for HR repair (Alan and
Ashworth, 2012).

Regulation of BRCA1 in mammalian cells

BRCA1 is regulated by poly-ubiquitination pathway
In Ruffner and Verma's report in 1997, BRCA1 was found undergoes
hyperphosporylation during G1 and S phase and starts dephosphorylation
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immediately after entering M phase, thus they concluded that BRCA1 is regulated
during different stages of cell cycle in a qualitative and quantitative manner
(Ruffner and Verma, 1997). Additionally, BRCA1's interaction and colocalization
with other DNA damage response protein such as BRCA1 Associated Ring
Domain 1 (BARD1) also exhibits a cell cycle dependent manner (Jin et al., 1997),
so, it's clear that BRCA1's expression is tightly regulated both the transcriptional
and protein level during different cell cycle stages, but very little is known about
how BRCA1's protein stability is controlled.
Previous publications have identified that F-box protein 44 (FBXO44)
mediates BRCA1's degradation in ubiquitination pathway by Skp1-Cul1-F-boxprotein 44 (SCFFBXO44) complex and such regulation is promoting the development
of sporadic breast cancer (Lu et al.,2012). Furthermore, E3 ligase HERC2 can also
specifically target BARD1-uncoupled BRCA1 and lead to the degradation of
BRCA1 in ubiquitination pathway; the depletion of HERC2 significantly reduced the
impact of the inactivation BARD1 and restored BRCA1 expression in vitro,
suggesting that HERC2 plays an critical role in destabilizing BRCA1 and
contributing to the breast carcinogenesis (Wu et al., 2010).

Interestingly, N-

terminus mediates the both binding between BRCA1 and SCFFBXO44, HERC2.

HERC2 and ubiquitination-proteasome pathway
Degradation of proteins involve two successive steps: load poly-ubiquitin by
covalent bonds to the targeted proteins and degradation of the proteins by 26S
proteasome complex.

In general, the ubiquitination pathways start with the
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activation of ubiquitin by E1 enzyme which is also known as ubiquitin-activating
enzyme, then E2 enzyme (also is called as ubiquitin-conjugating enzyme, UBC) will
lead the ubiquitin via thiol ester bond to bind the targeted proteins. The specific
targeting of E3 ligase is realized by the unique recognition motif and E3 ligase will
process the conjugation of ubiquitin to the targeted protein and facilitate the
synthesis of the poly-ubiquitin chain in multiple cycles. Even in most cases, E2
enzyme transfer the first ubiquitin moiety to the E3-bound substrate protein, and
then conjugate the following ubiquitin moiety to bound the previous one, but RING
finger targeted substrate allow E2 enzyme transfer the ubiquitin moiety directly to
the substrate.

Finally, ubiquitin will be removed by deubiquitinating enzymes

(DUBs) for recycle and ubiquitin-tagged proteins will be destructed into small
peptides by the 26S proteasome complex (Glickman and Ciechanover, 2002)
(Figure 5).
HERC2 gene is highly mutable and it was discovered from the deletion
hotspot on human chromosome 15q11-q13, HERC2 gene encodes a large protein
with a molecular weight of 528kDa (Lehman et al., 1998). Bioinformatics analysis
indicated its highly conserved function domains include RCC1-like domain and
COOH-terminal HECT domain, which are responsible for the Ran-dependent
membrane trafficking and E3 ligase function respectively By mediating ubiquitindependent recruitment of DNA damage repair proteins to damage chromosomes
and form complex with RNF8, HERC2 facilitates E2 ligase UBC13 to conjugate
with RNF8, in turn to regulate the expression levels of series repair proteins such
as 53BP1 and BRCA1 (Bekker-Jensen et al., 2010).
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Figure 1. Schematic Model for major DNA damage response kinase: ATM and
ATR Activation
(A) IR treatment forms DSBs and activates PARP1. Activation of the ATM
activity by MRN and TIP60 leads to the phosphorylation of CHK2, p53, and the γH2AX as well as downstream signaling cascade, which results in the recruitment of
MDC1, RNF8, RNF168, BRCA1, and 53BP1 to damage sites (B) UV or replication
stress lead to replication fork stalling and accumulation of RPA to coat on ssDNA,
then ATR/ATRIP as well as RAD17/ RFC2-5 complexes will be recruited to
damaged ssDNA. ATR kinase recruits the 911-associated protein TOPBP1 and
leads to the activation of the ATR signaling cascade and downstream CHK1
phosphorylation. Adapted from Ciccia and Elledge, Molecular Cell 40, 179-204
(2010) with permission from Elsevier.
-9-

Functional role of NPRL2/TUSC4 in suppress tumor proliferation and
maintain DNA damage response
Tumor Suppressor Candidate 4 (NPRL2/TUSC4) is also called Nitrogen
Permease Receptor 2-like (NPRL2), and it was first identified from lung cancer
homozygous deletion region which containing multiple tumor suppressor genes on
chromosome 3p21.3. NPRL2/TUSC4 gene contains 3.3kb with 11 exons coding for
a 1.5kb mRNA, and various splicing isoforms are expressed abundantly in normal
lung and testis tissues, NPRL2/TUSC4 (red in figure) conserved across species
ranging from yeast to chimpanzee with 33-66% aligned sequence (Figure 6).
Sequencing data indicated 1 out of 40 lung cancer cell lines contains a frameshift
mutation of NPRL2/TUSC4 gene which produces a stop codon (CAA to TAA Stop
codon 261 in H1514 cell line), NPRL2/TUSC4 gene encodes a 43 kd soluble
protein with an unknown protein binding domain (Lerman and Minna, 2000). In a
follow up paper in 2002, exogenous expression of NPRL2/TUSC4 by adenovirus
significantly inhibited the growth of Non Small Lung Cancer cell lines proliferation in
vitro and the cancer development in vivo, it also increased the apoptotic cells in
lung cancer cell lines which NPRL2/TUSC4 expression was originally disrupted, as
the programmed cellular response to stress and stimuli, the decreased apoptosis is
always considered as result of the inactivation of tumor suppressor, so these
results suggested the important roles of NPRL2/TUSC4 are playing in the
safeguard and maintenance of genomic stability ( Ji et al., 2002).
Additionally, inactivation of NPRL2/TUSC4 was found in multiple other
cancer types including renal and cervical cancers (Li et al., 2004). NPRL2/TUSC4
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was also found reciprocally correlated with the sensitivity of cisplatin (CDDP), a
commonly used anti-cancer drug which containing platinum and cause apoptosis in
cancer

cells.

Researchers

reintroduced

NPRL2/TUSC4

expression

in

NPRL2/TUSC4-null, cisplatin-resistant lung cancer cell line H322, and they were
able to resensitize the response of cell to cisplatin and increased the apoptotic cell
death, more specifically, the combination therapy with NPRL2/TUSC4-containing
nano-particles and cisplatin significantly reduced the tumor size and inhibited cell
proliferation

compare

to

cisplatin

treatment

alone.

This

result

indicated

NPRL2/TUSC4's potential role to mediate the DNA damage response and the
capacity to predict the clinical outcomes of cisplatin treatment in patients (Ueda at
al., 2006). The same research group published in 2010 again proved that the
increased sensitivity to cisplatin in NPRL2/TUSC4-null lung cancer cell line was
associated increased DNA damage response activities, reintroduction of
NPRL2/TUSC4 into cells by nanoparticles not only increased p-ATM, p-CHK1, pCHK2, γ-H2AX phosphorylated protein levels, which indicated the activation of
DNA damage response, but also showed that reintroduction of NPRL2/TUSC4
arrested cells into G2/M phases after cisplatin treatment, suggested cells with
NPRL2/TUSC4 would eventually undergo apoptosis process, which shed the light
to overcome cisplatin resistance and promote clinical efficacy (Jayachandran et al.,
2010).
Based on sequencing and bioinformatics analysis, it was believed an
unknown

protein-binding

domain

was

contained

at

the

N-terminal

of

NPRL2/TUSC4 protein. In 2008, Kurata and his colleagues found that
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NPRL2/TUSC4 can physically interact with 3-phosphoinositide-depedent protein
kinase-1 (PDK1) and prevent the binding of its co-activator Src to bind its
phosphorylation sites at tyrosine-9,-373 and -376 residues, thus inhibit the
activation of PDK1 and abolish the activity of AKT pathway, the depletion of
NPRL2/TUSC4 expression also promoted the cell proliferation (Kurata et al., 2008).
Furthermore, NPRL2/TUSC4 can also form complex with NPRL3 and DEPDC5,
the inhibition of this complex negatively regulate mTROC1 pathway and leading to
cells become more resistance to amino acid deprivation, and such cells are
hyperactive in term of growth and hypersensitive to mTROC1 inhibitor rapamycin,
this paper confirmed the tumor suppresor role of NPRL2/TUSC4 in the
maintenance of genome stability and regulation of cell as well as tumor growth
(Bar-Peled et al., 2013).
These studies consistently described that the inactivation of NPRL2/TUSC4
correlates with lower level of DNA damage response kinase activities and elevated
cell proliferation, while overexpression of TUCS4 is associated with inhibition of
tumor growth in various cancer types. Based on the accumulating evidences that
NPRL2/TUSC4 plays tumor suppressor functions in vitro and in vivo to maintain
genomic stability and inhibit tumorigenesis pathways by its binding domains, it's
reasonable to suspect that NPRL2/TUSC4 deficiency would lead to a compromised
DNA damage repair system such as HR repair and allow the potential increased
sensitivity of cells to DNA damaging drugs and therapeutics. And most likely these
regulation

would

occur

through

protein-binding
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regulation

considering

NPRL2/TUSC4 doesn't contain the domains responsible for phosphorylation or
other kinase activities.

Figure 2. BRCA1 mutations and breast cancer.
BRCA1 mutated women have 60% possibility to develop breast cancer before the
age of 70, while BRCA2 mutated women have 40% possibility and normal BRCA1
women have only 10%. Adapted from
www.cancer.gov/cancertopics/factsheet/Risk/BRCA.
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Figure 3.BRCA1 and its function network.
BRCA1 is associated with multiple pathways including DNA repair, cell-cycle
checkpoint regulation, ubiquitylation and transcriptional regulation. DNA damage
response triggers BRCA1 activation. Several damage sensors, including ATM/ATR
are activated in response to DNA damage. CHK2 is activated to prevent cell
division by mediating phosphorylation of BRCA1 and p53. BRCA2 and RAD51 can
form complex with FANCD2, then binds to BRCA1 and promotes S-phase or G2
arrest. BRCA1 forms a heterodimer with BARD1 to activate the ubiquitin-ligase
function. DNA repair by homologous recombination is mediated by the BRCA1associated surveillance complex which contains of BLM, MSH2–MSH6 and
MRE11–RAD50–NBS1. BRCA1 has been also shown to mediate X-chromosome
silencing, and also to mediate non-homologous end joining during DNA repair.
BRCA1 can form complexes to mediate chromatin remodeling and homologous
recombination. BRCA1 interacts with CHK1 to regulate apoptosis.
Adapted from Narod and Foulkes Nature Reviews Cancer 4, 665-676 (2010) with
permission from Elsevier.
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Figure 4. Schematic Model for major homologous recombination (HR) and
Non-homologous end-joining (NHEJ) repair.
DSBs can be repaired by one of two pathways: homologous recombination (HR)
or non-homologous end joining (NHEJ). Both pathways require recruitment of
MDC1 and the RNF8 as well as RNF168 ubiquitin E3 ligase to DNA damage sites.
The difference between the two pathways is that HR repair requires BRCA1 while
HNEJ repair is dependent on 53BP1 recruitment. In HR repair, the RAP80–BRCA1
complex is recruited through 2 pathways: either it binds to K63-linked poly-ubiquitin
chains attached to MDC1 or through interactions with hybrid SUMO-ubiquitin
chains. Adapted from Lu and Matunis Nature Structural & Molecular Biology 12,
1346-1348 (2013) with permission from Elsevier.
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Figure 5. Ubiquitin signaling of DNA double-strand breaks.
The signaling cascade of ubiquitylation events. E3 ligases specifically target their
substrates , examples are ( RING finger protein 8 (RNF8), HECT domain and
RCC1-like domain-containing protein 2 (HERC2), RNF168, BRCA1 and BRCA1associated RINg domain protein 1 (BARD1)) as shown above. E2 enzymes are
the ubiquitin-conjugating enzyme including UBC13, MMS2 and an unspecified E2.
X and Y stands for unidentified ubiquitylation targets. While E1 enzyme which is
also known as ubiquitin-activating enzyme is not shown above.
Adapted from Ulrich and Walden, Nature Reviews Molecular Cell Biology 11, 479489 (2010) with permission from Elsevier.
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Figure 6. NPRL2/TUSC4 gene tree.
Human NPRL2/TUSC4 (red in figure) conserved across species ranging from yeast
to chimpanzee with 33-66% aligned sequence. Image was generated by Ensembl
genome browser , gene ID: ENSG00000114388
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Chapter 2

MATERIALS AND METHODS

Cell cultures and plasmid
The U2OS, MDA-MB-231, and MCF-10A cell lines were purchased from the
American Type Culture Collection. McCoy’s 5A medium (CellGro;10-050-CV)
supplemented with 10% fetal bovine serum was used to maintain U2OS cells,
RPMI 1640 medium (Corning; 10-104-CV) supplemented with 10% fetal bovine
serum was used to culture MDA-MB-231 cells, and serum-free mammary epithelial
growth medium (Clonetics; CC-3051) containing insulin, hydrocortisone, epidermal
growth factor, and bovine pituitary extract was used to maintain MCF-10A cells. All
cells were incubated under humidified conditions in 5% CO 2. The pCMV5-3 ×Flag
vector plasmid was kindly provided by Dr. Funda Meric-Bernstam (The University
of Texas MD Anderson Cancer Center). The MD Anderson DNA Sequencing and
Microarray Facility confirmed the identities of all plasmids.

Antibodies and reagents
An anti-NPRL2/TUSC4 antibody was purchased from Proteintech (10157-1-AP), an
anti-BRCA1 antibody was purchased from Santa Cruz Biotechnology (sc-6954),
and anti-Flag M2 (F3165) and anti--actin (A2066) antibodies were purchased from
Sigma. Anti-HERC2 antibodies were purchased from BD Biosciences (612366).
MG132 was purchased from EMD Biosciences (133407-82-6), and cycloheximide
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was obtained from Sigma (C7698). G418 was purchased from Sigma (A1720).
Full-length NPRL2/TUSC4 was amplified using a TOPO TA cloning kit for
subcloning (Invitrogen; 45064) with the sense primer for the sequence of 5'AATGGGCAGCGGCTGCCGCA-3' and anti-sense primer for the sequence of 5'TCACTTCCAGCAGATGATGA-3'.

RNA Extraction and RT-PCR
RNA was extracted by TRIzol reagent (Life Technologies; 15596026) and reverse
transcription was conducted using SuperScript III kit (Invitrogen), and BRCA1 was
amplified using RT-PCR with the sense primer 5'-CAGCGATACTTTCCCAGAGC-3'
and anti-sense primer 5'-CTTGTTTCCCGACTGTGGTT-3'. Cyclophilin was used
as internal control.

RNA interference
Stable knockdown of NPRL2/TUSC4 expression was established via RNA
interference using lentiviral vector short hairpin RNA (Sigma; MISSION;
NM660545). NPRL2/TUSC4 was targeted with a lentiviral particle of MISSION
short hairpin RNA as well as MISSION nontargeted control particles. Western
blotting was performed after transduction to confirm the knockdown efficiency, and
puromycin was added to U2OS cell medium to maintain the NPRL2/TUSC4knockdown specificity. For transient transfection, human NPRL2/TUSC4 siRNA
was purchased from Thermo Scientific (On-Target; 10641), and the NPRL2/TUSC4
target

siRNA

sequences

were
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GCAUCGAACACAAGAAGUA

and

GACCCAAGAUCACCUAUCA. Human BRCA1 siRNA was purchased from
Thermo Scientific (On-Target; J-003461-09), and the BRCA1 target sequence was
CAACAUGCCCACAGAUCAA. Human HERC2 siRNA was purchased from
Thermo Scientific (On-Target; J-007180-09, J-007180-10, J-007180-11, and J007180-12),

and

the

HERC2

GCACAGUAUCACAGGUA-3',
GAUAAUACGACACAGCUAA-3',

target

sequences

were

5'-CGAUGAAGGUUUGGUAUUU-3',
and

5'5'-

5'-GCAGAUGUGUGCUAAGAUG-3',

respectively.

Immonuprecipitation and Immunoblotting
For immunoprecipitation of HERC2, BRCA1, and NPRL2/TUSC4, U2OS cells were
first transfected with an empty vector or FLAG-NPRL2/TUSC4 plasmids. After 72 h
of transfection, G418 was added to the medium for selection purposes. After stable
clones were isolated from the pool, whole cellular extracts were incubated with
RIPA buffer as described previously (Pierce et al,. 1999), and the products were
immunoprecipitated with an anti-FLAG M2 Affinity gel (Sigma; A2220) for 8 h at
4°C. After washing, the complexes were eluted with 3×FLAG peptide and
evaluated using sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(PAGE). For immunoprecipitation of the binding between HERC2 and BRCA1, cell
lysates were precleared with A/G Agarose beads (Santa Cruz Biotechnology; SC2003) and incubated with 1 g of antibody at 4 °C overnight. Precipitates were then
washed and suspended in 5× SDS buffer and submitted to SDS-PAGE and
immunoblotting. For immunoblotting, after samples were separated using
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electrophoresis, membranes were blocked with 5% milk diluted in Tris buffer with
0.1% Tween 20 for 1h at room temperature. The primary antibody was diluted in
5% bovine serum albumin in phosphate-buffered saline with sodium azide (Sigma;
S227) and then incubated with the membranes for 2 h at room temperature.
Subsequently, membranes were washed with phosphate-buffered saline with 0.1%
Tween 20 and incubated with secondary antibody. Finally, signals of the bound
antibody were detected using enhanced chemiluminescence (GE Healthcare;
RPN2232).

In vitro proliferation and PARP inhibition assays
MTT (Sigma; M5655) was used to evaluate the proliferation of cells. Briefly, cells
were counted and seeded in a 96-well flat-bottomed plate. After 96 h, cells were
incubated with MTT substrate (Sigma; 20 mg/ml) for 4 h, and the cultures were
removed and replaced with dimethyl sulfoxide. The optical density was measured
spectrophotometrically at 570 nm. The colony formation assay was performed by
seeding 200 cells in six-well plates. Olaparib and rucaparib were added to the
culture medium, and the cells were compared with untreated control cells. Colonies
were scored after 3 weeks. All experiments were repeated three times.

Microarray analysis
mirVana RNA isolation kit (Ambion) was used to isolate total RNA. Five hundred
nanograms of total RNA were used with a Sentrix Human-6 Expression Bead Chip
(Illumina) for labeling and hybridization. BeadArray Reader was used for chip
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scanning (Illumina). As described previously (Peng et al., 2014), the gene
expression profile was subjected to normalization and log2 transformation. The
NextGENe software program was used to identify genes whose expression differed
in two clusters, and a t-test was used to separate genes with significantly different
expression (P < 0.001). The Ingenuity Pathway Analysis system was used for gene
enrichment analysis.

Homologous recombination repair and flow cytometry analyses
The plasmids DR-GFP, pCAGGS, and pCBASce were gifts from Dr. Maria Jasin
(Memorial Sloan-Kettering Cancer Center). U2OS cells were first treated with
NPRL2/TUSC4 and BRCA1 siRNA as well as control siRNA for 24 h. BRCA1containing plasmids were then transfected into NPRL2/TUSC4-knockdown cells to
induce re-expression of BRCA1. After 48-72 h, flow cytometry was performed to
detect GFP-positive cells using a FACSCalibur and the CellQuest software
program (Becton Dickinson). Three independent experiments were performed to
obtain mean values and their standard deviations. Cell-cycle analysis was
performed at the MD Anderson Cancer Center Flow Cytometry and Cellular
Imaging Facility.

Tumor growth in nude mice and immunohistochemistry
Six-week-old female nude mice were used in this study. The MD Anderson
Institutional Animal Care and Use Committee approved the animal protocol. 5 × 106
MDA-MB-231 cells with and without NPRL2/TUSC4 overexpression or 1 × 107
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MCF-10A cells with and without knockdown of NPRL2/TUSC4 expression were
injected to the mammary fatpads of mice. Tumors were measured from 1 week
after MDA-MB-231 cells injection and monitored weekly, whereas MCF-10A tumors
were observed 1 month after cell injection. At least five nude mice were used for
each group. Human breast tissue samples (Biomax) were embedded in Xylene and
100%, 95%, 70%, 50% ethanol respectively for deparaffinization, slides were then
incubated with NPRL2/TUSC4 antibody at 4º overnight followed by antigen
retrieval. Then samples were processed and evaluated immunohistochemically
under microscope after being dehydrated and stabilized.

Transfection and ubiquitination assay
U2OS cell transfection was conducted using Oligofectamine (Life Technologies;
12252-001). Plasmids encoding HA-tagged ubiquitin were transfected in U2OS
cells with and without knockdown of NPRL2/TUSC4 expression. Forty-eight hours
after transfection, cells were harvested and lysed with RIPA buffer. Cell lysates
were then incubated with Ni2+ beads (Amersham Pharmacia Biotech) to pull down
histidine-tagged BRCA1 with the beads. Precipitated BRCA1 protein was isolated
using SDS-PAGE and detected using an anti-HA antibody (Sigma; ab18181).

Immunoflurosence foci staining
Cells were cultured on cover slips in 6-well plates before staining for 24 hours, then
growth medium was removed and cells were washed by ice-cold PBS twice. Then
cells were incubated by cytoskeleton buffer (10mM PIPES, Ph6.8, NaCl 100mM,
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Sucrose 300mM, MgCl2 3mM, EGTA 1mM,Triton X100/ 0.5%) for 3 min on ice,
then cells were washed with PBS for 3 times and incubate in stripping buffer (Tris
HCL 10mM, NaCl 10mM, MgCl2 3mM, Tween 20/1%, Sodium deoxychalate 0.25%)
for 3 min on ice. After wash with PBS for 3 times, cells were then fixed in 4% PFA
overnight at 4 degrees. After that, cells were permeabilized in 1% Triton X-100 and
0.5% NP-40PBS for 30 mins and blocked in 5% horse serum/1% goat serum
mixture for 1 hour at room temperature. Samples were incubated with primary
antibody in blocking buffer for 2 hours at room temperature, followed by 0.01%
Triton-PBS wash and Fluor 488 and 594 conjugated secondary antibody (Life
Technologies, 1:500) incubation for 1 hour at room temperature. Lastly, samples
were mounted with DAPI antifade medium for microscope analysis.

Microscopy analysis
DNA damage foci staining images were captured with fluorescent microscope
(Nikon, Eclipse E800). 60X oil objective lens (Plan Fluor, NA 1.3) and CCD camera
(QImaging, Qiclick F-M-12) were equipped to facilitate the analysis and images
capture were processed by the Nikon NIS-Elements system.

HU recovery and checkpoint assay
Cells were incubated in medium with or without HU (2 mM) for 24 hours. Then HU
was removed, and cells were harvested at 0, 8, and 16 hours after release.
Harvested cells were fixed in ethanol, stained with propidium iodide, and analyzed
by FACS. For HU followed by Taxol, cells were untreated or treated with HU (2
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mM) for 24 hours. Then HU was removed by replacing fresh medium, Taxol was
added and harvested cells at 0, 8, 16 hours, cells were then fixed in ethanol and
stained using phospho-histone H3 (Ser10)-specific antibody (p-H3) and propidium
iodide (PI).

Statistical Analysis
All statistical analyses were performed with a two-tailed Student's t-test.
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CHAPTER 3
NPRL2/TUSC4 REGULATES BRCA1'S STABILITY BY BLOCKING ITS
PHYSICAL INTERACTION WITH HERC2

Results
NPRL2/TUSC4 expression is reduced in breast cancer and correlates with
breast cancer progression
To characterize whether NPRL2/TUSC4 expression is associated with
breast cancer, we performed Western blotting to measure the expression of
NPRL2/TUSC4 in non-transformed breast cell lines, including HMEC, MCF-10A,
and MCF-12A, and breast cancer cell lines with both luminal and basal subtypes
(Figure 7A). We observed that NPRL2/TUSC4 expression was markedly higher in
the non-transformed cell lines than that in breast cancer cell lines. We also
evaluated NPRL2/TUSC4 expression in normal breast tissue and breast
carcinomas using immunohistochemical staining, and found that NPRL2/TUSC4
expression was lower in the tumors than that in matched adjacent normal breast
tissue (Figure 7B). Furthermore, The Cancer Genome Atlas-based analysis of
mRNA expression in invasive breast carcinomas demonstrated a significant
difference between the survival rates in patients with unaltered NPRL2/TUSC4
expression and those with downregulated NPRL2/TUSC4 expression (P =
0.000005). Specifically, the survival rate of 100 months was 24.7% in 889 patients
with downregulation of NPRL2/TUSC4 expression (Z-score threshold, ±1), while
the survival rate in these patients dropped sharply to 0% after 100 months. In
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comparison, the survival rate was 40% in patients with unaltered NPRL2/TUSC4
expression after 200 months, with a P value less than 0.0001 (Figure 8A).
Comparison of patients with upregulated and unaltered NPRL2/TUSC4 expression
did not demonstrate any significant differences in survival rate (Figure 8B). Total of
889 breast carcinoma patients has 65.20% without TUSC4 alteration, 24.70% with
TUSC4 level down-regulation, 9.40% up-regulation and 0.6% mutation (Figure 8C).
These results strongly suggested that low NPRL2/TUSC4 expression is associated
with the cancer phenotype, indicating that NPRL2/TUSC4 may play an important
role as a tumor suppressor in breast cancer patients. Based on the sequencing
data of first 467 patients, there were 79 basal-like breast carcinoma patients, 203
luminal A patients and 112 luminal B patients which account for 16.9%, 43.5%,
24% of the total patients number respectively. Further sequencing data is
necessary to complete the subtypes profiles for the rest of the patients. Future
studies will need to establish the relationship between TUSC4 expression level and
different breast cancer subtypes in terms of patients' survival rates.
To

systematically

evaluate

the

tumor-suppressive

function

of

NPRL2/TUSC4, we performed microarray analysis comparing NPRL2/TUSC4knockdown cell lines and control cell lines (Figure 9B). We then examined the
differentially expressed genes in these cells using the Ingenuity Pathway Analysis
system (QIAGEN). Comparison of the NPRL2/TUSC4-knockdown and control cells
ranked cancer as one of the top disease and disorder pathways, further suggesting
that NPRL2/TUSC4 functions as a tumor suppressor gene (Figure 9C).
Additionally, high portion of genes in NPRL2/TUSC4-deficient gene signatures
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were involved in canonical pathways such as DNA damage response and breast
cancer regulation (Figure 9D).
Owing to the low NPRL2/TUSC4 expression in breast cancer and the
association with poor breast cancer patient survival rates, we explored the role of
NPRL2/TUSC4 in the development of breast cancer and the possible functional
pathways that NPRL2/TUSC4 is involved in. It has been previously reported that
multiple cancers have mutations in or epigenetically silenced HR related genes,
which indicated potential association between HR repair deficiency and cancer
development (Deng and

Wang 2003; Lord and Ashworth 2002 ). Thus, we

suspected that low expression of NPRL2/TUSC4 contributes to the deficiency of
HR repair, which also drives genomic instability in breast cancer development. We
performed a cluster analysis of a NPRL2/TUSC4-knockdown microarray signature
with previously established HR repair deficiency (HRD) gene signatures (Peng et
al, 2014). The heat map demonstrated that NPRL2/TUSC4-deficient cells formed a
cluster with HRD gene signatures (Figure 9A), whereas the control cells separated
from NPRL2/TUSC4-knockdown samples. Considering the fact that the HRD
signature described above was discovered under the condition of loss of tumor
suppressor BRCA1, the results suggested a potential correlation and molecular
similarity between NPRL2/TUSC4 knockdown cells and BRCA1-deficient HR repair
deficiency.
By analyzing the well defined triple negative breast cancer cell lines makers,
we also identified that NPRl2/TUSC4 has lower expression in basal-like cell lines
compare to luminal types (Figure 9 E,F). Furthermore, RPPA analysis indicated
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knockdown of TUSC4 U2OS cells exhibited similar gene clusters with BRCA1
knockdown cells compare to control cells (Figure 9G).

NPRL2/TUSC4 is widely expressed in both cytoplasm and cellular nucleus
We next examined the distribution of NPRL2/TUSC4 in cells. First, by damage
foci staining, we found NPRL2/TUSC4 can form DNA damage foci in cells after
both IR and UV, indicated the potential functions of NPRL2/TUSC4 in DNA
damage response pathways (Figure 10). Additionally, chromatin fractionation
assay indicated NPRL2/TUSC4 is widely distributed in both cytoplasm and
nucleus, furthermore, data also identified NPRL2/TUSC4 is a chromatin binding
protein, further suggested its possible functions in DNA damage response (Figure
11).

NPRL2/TUSC4 knockdown impairs HR repair by downregulation of BRCA1
expression
The major conserved pathway used in mammalian cells to maintain genetic
integrity and DNA fidelity is HR repair (Sung and Klein 2006; Lieber et al., 2003).
Here, we have identified an association between expression profile of
NPRL2/TUSC4 knockdown and BRCA1 deficient HRD gene signature. We
suspected that loss of NPRL2/TUSC4 will also affect the foci formation of BRCA1,
so we carried out phenotypic examination to test whether NPRL2/TUSC4 is
required for BRCA1 foci formation by immunostaining. We performed BRCA1 foci
staining followed by IR and UV irradiation. NPRL2/TUSC4 knockdown significantly
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demolished the BRCA1 foci formation after irradiation, whereas control small
interfering RNA (siRNA) did not affect the formation of BRCA1 foci (Figure 12, 13).
We further evaluated HR repair efficiency by the standard HR repair analysis
system (Pierce et al, 1999; Peng et al., 2009) with NPRL2/TUSC4-deficient U2OS
model cells. More specifically, the DR-GFP reporter substrate was incorporated
into cellular genomic DNA. SceGFP contains an I-SceI endonuclease site within
the coding region, which abolishes GFP expression. iGFP is a truncated GFP,
which contains homologous sequence for the SceGFP. Expression of I-SceI
induces a single DSB in the genome. in normal cells, this DSB can be repaired by
HR repair , the expression of GFP can be restored, while in HR deficient cells, the
DSB cannot be repaired, the expression of GFP will be significantly reduced and
analyzed by flow cytometry to indicate the efficiency of HR repair (Figure 14B). We
found that NPRL2/TUSC4-knockdown cells had a significant decrease of HR
reporter activity compared to control cells, which suggested impaired HR repair
efficiency (Figure 14A). We used BRCA1-knockdown cells as a positive indicator of
homologous

recombination

repair

to

confirm

the

HR

repair

efficiency.

NPRL2/TUSC4-knockdown cells presented comparative reduction in HR repair
efficiency as BRCA1-knockdown cells, which were around 40-50% lower than that
in control cells. To confirm that the defective HR repair efficiency was not caused
by transfection efficiency or inaccurate efficiency from I-SceI, we reintroduced
BRCA1 expression into the NPRL2/TUSC4-knockdown cells and observed a
significant increase in HR repair efficiency over that in NPRL2/TUSC4-knockdownonly cells (P < 0.05).
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Surprisingly, we found that knockdown of NPRL2/TUSC4 expression
reduced the BRCA1 protein expression (Figure 14C), indicating that the decrease
in HR repair efficiency in the NPRL2/TUSC4 knockdown cells may have resulted
from abnormal BRCA1 protein expression. These results are consistent with our
above findings that NPRL2/TUSC4-knockdown cells have HRD gene expression
patterns similar to those in BRCA1-deficient cells which were used to generate our
HRD gene signatures. These results revealed for the first time a novel function of
NPRL2/TUSC4 in that disruption of its expression decreases BRCA1 expression
and functions. Furthermore, BRCA1 and NPRL2/TUSC4 knockdown significantly
reduced the HR repair efficiency compare to control, while NPRL2/TUSC4
knockdown with BRCA1 overexpression restored the HR repair, double knockdown
of both genes further reduced HR repair efficiency (Figure 27).
Additionally, about 1% of patients carry BRCA1 mutation, and the log-odds
ratio between BRCA1 mutation and down-regulated NPRL2/TUSC4 is 0.875, which
indicates the tendency of co-occurrence. However, the p-value is 0.102, suggesting
there in no significant correlation. Thus, the BRCA1 mutation and down-regulated
NPRL2/TUSC4 are not mutually exclusive nor co-occurring.

NPRL2/TUSC4 regulates BRCA1 protein stability
We then investigated whether BRCA1 mutation is associated with
NPRL2/TUSC4 expression level, as we expected, NPRL2/TUSC4 is not correlated
with BRCA1 mutation in breast cancer patients (Figure 15A). We next sought to
determine how NPRL2/TUSC4 affects BRCA1 protein expression. To that end, we
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first sought to determine whether reduced BRCA1 protein expression after
NPRL2/TUSC4 knockdown was caused by altered cell-cycle distribution because
BRCA1 expression has known to be cell-cycle regulated. We carried out a cellcycle analysis and did not observe a significant difference in G1-, G2/M-, or Sphase distribution between control and NPRL2/TUSC4-knockdown cells (Figure
15B), indicating that

decreased BRCA1

expression

after

NPRL2/TUSC4

knockdown was not resulted from the cell-cycle shift. To further determine whether
such changes occur through transcriptional regulation, we performed quantitative
reverse transcriptase-polymerase chain reaction to measure the BRCA1 mRNA
expression in control cells and cells with NPRL2/TUSC4 knockdown. We identified
no significant BRCA1 mRNA differences after NPRL2/TUSC4 knockdown (Figure
15C), thus ruling out the possibility that BRCA1 expression by NPRL2/TUSC4 was
regulated at the mRNA level.
Next, we sought to determine if NPRL2/TUSC4 regulates BRCA1 protein
stability. To answer this question, we conducted BRCA1 protein stability
experiments by treating control and NPRL2/TUSC4-knockdown U2OS cells with
cycloheximide, for the purpose of blocking protein synthesis. As shown in Figure
16A, NPRL2/TUSC4 knockdown reduced the half-life of BRCA1 from about 20 h to
less than 6 h, suggesting that NPRL2/TUSC4 plays an essential role in stabilizing
BRCA1 at the protein level (Figure 16 B,C). Additionally, to determine whether
BRCA1 protein stability is regulated by NPRL2/TUSC4 via the proteasome
pathway, we treated control and NPRL2/TUSC4-knockdown U2OS cells with the
proteasome inhibitor MG132. As shown in Figure 17, MG132-based treatment
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restored the BRCA1 expression in cells with NPRL2/TUSC4 knockdown but only
slightly increased the BRCA1 protein expression in control cells. This result
suggested that NPRL2/TUSC4 regulates BRCA1 protein stability via the
proteasome-dependent pathway.

NPRL2/TUSC4 regulates BRCA1 protein stability via ubiquitination pathway
It has been previously reported that HERC2 is an E3 ligase that targets BRCA1 for
degradation (Jin et al., 1997). To determine whether NPRL2/TUSC4 regulates
BRCA1 stability via HERC2, we performed ubiquitination assay by transfecting
hemagglutinin

(HA)-tagged

ubiquitin

plasmids

into

cells

with

or

without

NPRL2/TUSC4 knockdown, followed by immunoprecipitation with control IgG or an
anti-BRCA1 antibody. Surprisingly, we observed no signs of ubiquitination
regardless of the NPRL2/TUSC4-knockdown status. However, after treatment with
MG132, Western blotting for HA-tagged ubiquitin showed that NPRL2/TUSC4knockdown cells underwent heavy ubiquitination, whereas control cells exhibited
only a light polyubiquitination ladder (Figure 18), indicating that knockdown of
NPRL2/TUSC4 expression caused a robust increase in BRCA1 protein
polyubiquitination. We also confirmed previous findings that downregulation of
expression of HERC2 led to increased expression of BRCA1 regardless of the
presence of NPRL2/TUSC4 (Figure 19A, B). Under both conditions, BRCA1
expression was markedly upregulated after depletion of HERC2.
The next question to be answered was whether NPRL2/TUSC4 participates
in ubiquitination of BRCA1 via HERC2 indirectly or stabilizes BRCA1 directly. We
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performed immunoprecipitation with established NPRL2/TUSC4-overexpressing
U2OS cell lines to determine the relationships among NPRL2/TUSC4, BRCA1, and
HERC2. Reciprocally, we found that NPRL2/TUSC4 physically interacts with
HERC2 but not with BRCA1 (Figure 20), which strongly suggested that
NPRL2/TUSC4 regulates BRCA1 stability via interaction with HERC2. Considering
the previously reported binding functions of NPRL2/TUSC4 (Ueda et al., 2006;
Jayachandran et al, 2010) (Figure 22), we suspected that NPRL2/TUSC4 may
prevent physical interaction between BRCA1 and HERC2. The binding between
these two proteins (Wu et al, 2010) has been previously described, so we
performed further immunoprecipitation to determine whether overexpression of
NPRL2/TUSC4 weakens this binding. As shown in Figure 21, endogenous HERC2
physically bound to BRCA1. Intriguingly, overexpression of NPRL2/TUSC4
interrupted

the

binding

between

HERC2

and

BRCA1,

indicating

that

NPRL2/TUSC4 may regulate BRCA1 stability by preventing physical interaction
between BRCA1 and HERC2. Additionally, BRCA1 expression level is negatively
associated with HERC2 expression level in breast cancer cell lines (Figure 27).
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A.

B.

Figure 7. Low NPRL2/TUSC4 expression level in breast cancer
A. Lower NPRL2/TUSC4 expression levels was found in both luminal and
basal types of breast cancer cell lines, while non-transformed breast cell
lines (HMEC, MCF-10A and MCF-12A) exhibited higher NPRL2/TUSC4
level.
B. IHC staining indicated normal breast tissue (left) expressed higher
NPRL2/TUSC4 protein level than breast cancer tissues (right), and bar
graphs also indicated the quantified NPRL2/TUSC4.

- 35 -

A.

B.

- 36 -

C.

Figure 8. Low NPRL2/TUSC4 expression level is associated with poor
survival rate
A. 24.7% breast cancer patients showed low NPRL2/TUSC4 expression level, and
the low NPRL2/TUSC4 level correlates with poor survival rate (p=0.00005, data
adapted from cBio portal for Cancer Genomics). B.9.4% of up-regulation of
NPRL2/TUSC4 expression patients out of 889 in total didn’t show significant
change of survival rate compared to TUSC4 non-altered patients, with p value of
0.672; C.total of 889 breast carcinoma patients has 65.20% without NPRL2/TUSC4
alteration, 24.70% with NPRL2/TUSC4 level down-regulation, 9.40% up-regulation
and 0.6% mutation.
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A.

B.
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C.

D
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E

F
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G

Figure 9. NPRL2/TUSC4 is associated with HR defect genes and breast
cancer phenotypes.
A. NPRL2/TUSC4 knockdown microarray gene expression profiles were clustered
with previously identified 230 homologous recombination defect gene signature,
genes with p<0.001 and log ratio 0.1 were separated to generate heat map
between NPRL2/TUSC4 knockdown cells and control cell lines.
B. Gene expression analysis identifies NPRL2/TUSC4 knockdown gene signature.
The analysis was performed using NexusExp3 array tools. Heat map of the
NPRL2/TUSC4 knockdown gene signature, consisting of 263 genes whose
expression differed from control cell lines. Microarray was conducted in three
independent samples of control cells and three independent samples of
NPRL2/TUSC4 knockdown cell line. Student’s t-test was conducted between the
average of control cells and that of knockdown cells (p<0.00001).
C. IPA analysis of NPRL2/TUSC4 knockdown cells' top pathways changed.
D. Top canonical pathways in terms of number of genes in NPRL2/TUSC4deficient gene signature on analysis with Ingenuity Pathway Analysis Software.
Genes with ±1.25 fold change and p value less than 0.05 were selected and
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imported into IPA system. Significance refers to the log (p value), which was
calculated by IPA program using Fisher’s exact test. Threshold is at p= 0.05.
E. NPRL2/TUSC4 is associated with different phenotypes of breast cancer cell
lines.
F. Low NPRL2/TUSC4 expression level is associated with breast cancer
phenotypes. Normal or non-transformed breast cell lines has relatively higher
expression level than luminal and basal-like breast cancer cell lines, the p value is
less than 0.05.
G. RPPA analysis indicated NPRL2/TUSC4 knockdown cells shared similar cluster
patterns with BRCA1 knockdown cells.
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Figure 10. NPRL2/TUSC4 forms DNA damage foci after irradiation
NPRL2/TUSC4 forms DNA damage foci after both types of irradiation in U2OS
cells, under the conditions of both IR and UV, while the foci were not observed in
the NPRL2/TUSC4 knockdown cells, as well in the non treated cells.
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Figure 11. NPRL2/TUSC4 widely spreads in both cytoplasm and nuclear
Nuclear fractionation definitions are described below, F1-Cytoplasm, F2- Washing
supernatant from Cytoplasm, F3-Soluble Chromatin proteins, F4-Chromatin bound
proteins. U2OS control and NPRL2/TUSC4 Flag tag overexpression cells were
used from left to right.
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Figure 12. NPRL2/TUSC4 knockdown reduced BRCA1 protein foci after UV
NPRL2/TUSC4 knockdown reduced BRCA1 foci formation after UV, while control
cells (NT) didn’t have such effect. p-RPA indicated the efficiency of irradiation.
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Figure 13. NPRL2/TUSC4 knockdown reduced BRCA1 protein foci after IR
NPRL2/TUSC4 knockdown reduced BRCA1 foci formation after IR, while control
cells didn’t have such effect (NT). γ-H2AX indicated the efficiency of irradiation.
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A.

B.
NPRL2/TUSC4 knockdown reduced HR repair efficiency and BRCA1 protein

expression level
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C.

Figure 14. NPRL2/TUSC4 knockdown reduced HR repair efficiency and
BRCA1 protein expression level
A. NPRL2/TUSC4 knockdown significantly reduced HR repair efficiency compared
to control (p<0.05), while reintroduction of BRCA1 expression into
NPRL2/TUSC4-knockdown cells rescued the HR repair efficiency (p<0.05).
B. Simplified schematic of the DR-GFP reporter assay for HR repair, Adapted
from Lutzmann, Molecular Cell 47, 523--534 (2012) with permission from
Elsevier.
C. Western blotting confirmed NPRL2/TUSC4, BRCA1 knockdown and
overexpression of BRCA1 after NPRL2/TUSC4 knockdown. BRCA1 intensity
normalized to NPRL2/TUSC4 was measured by Image J.
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Figure 15. NPRL2/TUSC4 knockdown decreased BRCA1 is not through cell
cycle distribution
A. BRCA1 mutation is not associated with NPRL2/TUSC4 expression level. Data
was generated from database Oncomine, Pawitan breast cancer cell samples;
B. Knockdown of NPRL2/TUSC4 didn’t significantly change the cell cycle
distribution of U2OS cells compared to control cells. G1, G2/M and S phases cells
were indicated by percentage of total cell numbers.
C. NPRL2/TUSC4 knockdown cells didn’t show significant decrease of BRCA1
mRNA by qRT-PCR compared to control cells. The values of each column were
normalized to the value of cyclophilin.
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Figure 16. Knockdown of NPRL2/TUSC4 decreased BRCA1 stability in CHX
assay
A. NPRL2/TUSC4 knockdown U2OS cells showed shortened half-life of BRCA1
level compared to control cells. All cells were treated with 1μM of CHX for 0 to
24 hours.
B. Curves of BRCA1 level normalized to 0h after CHX treatment, while blue curves
indicated control cells, and red curves indicated NPRL2/TUSC4 knockdown
cells.
C. Bar graph of BRCA1 half-life. Control cells have BRCA1 half-life about 20 hours,
while NPRL2/TUSC4 knockdown cells have BRCA1 half-life about 5 hours.
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Figure 17. NPRL2/TUSC4 regulates BRCA1 stability via proteasome
degradation pathway
NPRL2/TUSC4 knockdown U2OS cells showed shortened half-life of BRCA1 level
compared to control cells. All cells were treated with 1μM of CHX for 0 to 24 hours.
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Figure 18. NPRL2/TUSC4 regulates BRCA1 stability via ubiquitination
pathway
NPRL2/TUSC4 knockdown increased ubiquitination level of BRCA1 compared to
control cells (After MG132 enrichment for ubiquitination).

- 55 -

A.

B.
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Figure 19. HERC2 is E3 ligase to regulate BRCA1's stability
A. HERC2 knockdown rescued BRCA1 expression level, with and without the
presences of NPRL2/TUSC4.
B. Bar graph indicated a significant BRCA1 reduction after NPRL2/TUSC4
knockdown (p<0.05), BRCA1 increases after HERC2 knockdown with
NPRL2/TUSC4 presence (p<0.05), or without NPRL2/TUSC4 (p<0.001). All
values were compared to control cells.
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Figure 20. NPRL2/TUSC4 physically interacts with HERC2 but not BRCA1
3XFlag control and NPRL2/TUSC4-Flag tag U2OS cells were used to perform
Immunopercipitation. Total of 4mg of protein were used in each IP conditions, and
2% input were loaded as control and indicate the overexpression of TUSC4.
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Figure 21. NPRL2/TUSC4 overexpression reduced the binding between
BRCA1 and HERC2
NPRL2/TUSC4 overexpression reduced the binding between BRCA1 and HERC2
in Hela cell lines. 2% input were used to indicate the level of HERC2, IgG control
antibody and BCRA1 antibody were used to perform IP in both control cells and
NPRL2/TUSC4 overexpression cells. Total of 4mg of protein were used to perform
in each condition.
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A.

B.

Figure 22. BRCA1 interacts with HERC2 and HERC2 regulates BRCA1
depends on BRAD1
A. BRCA1 physically interacts with HERC2 regardless of the irradiation.
B. HERC2 degrades BARD1-uncoupled BRCA1 in the CHX treatment, BRCA1 is
destabilized while BARD1 is deficient; and BRCA1 is stabilized when HER2 is
depleted. Adapted from Wu et al., Cancer Research 70, 6384-6392 (2010) with
permission from Elsevier.
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Figure 23. Simplified model of the mechanism NPRL2/TUSC4 stabilizes
BRCA1
When NPRL2/TUSC4 is depleted in breast cancer, HERC2 has increased binding
to BRCA1, thus ubiquitinates BRCA1 and degrades in proteasome-depedent
pathway; while TUSC4 is overexpressed, TUSC4 prevents the binding between
HERC2 and BRCA1, thus stabilize BRCA1.
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Figure 24. Predicted model of the mechanism NPRL2/TUSC4 stabilizes
BRCA1 through BARD1
When NPRL2/TUSC4 is depleted in breast cancer, HERC2 has increased binding
to BRCA1/BARD1 complex, thus ubiquitinates BRCA1 and degrades in
proteasome-depedent pathway; while NPRL2/TUSC4 is overexpressed, TUSC4
prevents the binding between HERC2 and BRCA1, and enhances the
BRCA1/BARD1 binding. thus stabilize BRCA1.
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Figure 25. NPRL2/TUSC4 and BRCA1 double knockdown further reduced HR
repair efficiency.
A. BRCA1 and NPRL2/TUSC4 knockdown significantly reduced the HR repair
efficiency compare to control, while NPRL2/TUSC4 knockdown with BRCA1
overexpression restored the HR repair, double knockdown of both genes further
reduced HR repair efficiency.
B. Western blot confirmed the NPRL2/TUSC4 and BRCA1 knockdown efficiency
and overexpression level of BCRA1.
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Figure 26. NPRL2/TUSC overexpression is associated lower breast cancer
proliferation rates
NPRL2/TUSC4-flag tag overexpression exhibit significant slower proliferation rates
in both MDA-AB-231 cell line and MCF-7 cell line. In 231 cells, clone #7 and #13
were used to compare with 3xF flag control in both MTT and colony formation
assay(upper panel); In MCF7 cells, clone #1 and #4 were used to compare with
3xF flag control in both MTT and colony formation assay(lower panel)
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Figure 27. BRCA1 expression level is negatively associated with HERC2
expression level in breast cancer cell lines.
MDA436, SCBR3, HCC1937,MDA231,T47D, MCF7, MCF12A, HMEC and
MCF10A were used to conduct the western blot; expression level of BRCA,
HERC2 were evaluated, and tublin were used as loading control.
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CHAPTER 4

NPRL2/TUSC4 FUNCTIONS AS TUMOR SUPPRESSOR PROTEIN IN BREAST
CANCER
RESULTS
NPRL2/TUSC4 suppresses the tumorigenicity of human breast cancer cells
We have identified NPRL2/TUSC4 functions as tumor suppressor gene in
breast cancer, possibly through positively regulating BRCA1. Next, we postulated
that overexpression of NPRL2/TUSC4 also suppresses breast tumor proliferation in
vitro and in vivo. To validate this, we compared the proliferation rate of the breast
cancer cell line MDA-MB-231 with or without NPRL2/TUSC4 overexpression.
Colony formation assays indicated markedly reduced proliferation of the
NPRL2/TUSC4-overexpressing cells (Figure 26, 30). Because NPRL2/TUSC4
effectively inhibits breast cancer cell growth in vitro, we further examined the effect
of NPRL2/TUSC4 overexpression in a xenograft mouse model of breast cancer.
We injected female mice with control or NPRL2/TUSC4-overexpressing MDA-MB231cells into the mammary fatpads. We then monitored and measured tumor
growth weekly. By week 6 after injection, 5 of 10 mice injected with
NPRL2/TUSC4-overexpressing cells remained tumor-free, whereas all 5 mice
injected with control 231 cells had large tumors (Figure 28 A, B; Table 1).

NPRL2/TUSC4 knockdown transforms normal mammary epithelial cells
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Previous reports indicated that HR repair defect sensitizes cancer cells to
DNA damaging drug (Foray et al., 1999; Deng and Wang 2003) and the poly(ADPribose) polymerase (PARP) inhibitor (Alli et al, 2009; Powell et al., 2003). Thus,
NPRL2/TUSC4 deficiency cells with HR repair defect are highly likely to be more
sensitive to the treatment of PARP inhibitor, which can effectively inhibit the repair
of single strand DNA break. To confirm this hypothesis, we performed colony
formation assay in U2OS cell with NPRL2/TUSC4 knockdown after PARP inhibitor
Olaparib and Rucaparib treatment, as well as control cells. As we expected, both
drug significantly reduced the colony formation in NPRL2/TUSC4 knockdown cells
compared the control cells (Figure 29 A, B). Additionally, we examined
NPRL2/TUSC4 depletion to determine whether it initiates breast tumor
development in a xenograft mouse model. We injected MCF-10A cells with stable
knockdown of NPRL2/TUSC4 expression and the control cells into the mammary
fatpads of female nude mice. Similarly to the procedure described above, we
closely monitored tumor formation in the mice. Notably, tumors began to form in 3
of 10 mice injected with NPRL2/TUSC4-knockdown cells after 3 weeks, whereas
no tumors formed in the control groups (Table 2). These results demonstrated that
loss of NPRL2/TUSC4 expression alone is sufficient to initiate malignant
transformation of immortalized nontransformed mammary epithelial cells, which is
consistent with our hypothesis that NPRL2/TUSC4 functions as a bona fide tumor
suppressor in breast cancer.
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NPRL2/TUSC4 also regulate the foci formation of Rad51
We also performed Rad51 foci staining followed by IR irradiation.
NPRL2/TUSC4 knockdown significantly demolished the BRCA1 foci formation after
irradiation, whereas control small interfering RNA (siRNA) did not affect the
formation of Rad51 foci. Previous reports has suggested BRCA1 promote the
recruitment of Rad51 and Rad51 forms complex with BRCA1 in the HR repair, it's
highly likely the knockdown of NPRL2/TUSC4 reduced BRCA1 expression and
further lead in the Rad51 foci formation decrease (Figure 31 A, B).

NPRL2/TUSC4 knockdown delays cell cycle after irradiation
We have proven that knockdown of NPRL2/TUSC4 under normal
conditions, next we sought to investigate if NPRL2/TUSC4 is associated with cell
cycle arrest under stress conditions. So, we added hydroxyurea (HU) into medium
cultured with both control cells and NPRL2/TUSC4 knockdown cells, we observed
that NPRL2/TUSC4-deficient cells exhibited noticeable slower cell cycle recover
from G1 arrest compare to control cells and NPRL2/TUSC4 deficient cells with
reintroduction of NPRL2/TUSC4 plasmid transfected cells. All the samples were
also treated with Taxol which is widely used in cell biology to cause G2/M phase
arrest. After 8 hours of Taxol treatment, control cells were already arrested in G2
while both NPRL2/TUSC4 deficient and NPRL2/TUSC4 transfected cells were still
blocked in G1, but after 16 hours of treatment, NPRL2/TUSC4 deficient cells were
shifted into G2 arrest, while both control cells and NPRL2/TUSC4 transfected cells
were able to break the G2 arrest (Figure 32).
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As an alternative way to evaluate the if cells can recover from stress,
phosphorylated histone 3 is used to indicate the mitosis activity, so we also
performed p-H3 staining to evaluate if proliferation rate of NPRL2/TUSC4 deficient
cells were affected. As shown in figures, after 8 hours and 16 hours of Taxol
treatment followed by HU removal, control cells had 1.28% and 12.8% p-H3
positive population while NPRL2/TUSC4 deficient cells had only 0.82% and 5.86%
p-H3 positive population respectively, that was about 50% decrease of mitotic level
compare to control cells. NPRL2/TUSC4 transfected sample didn’t display high pH3 as the control cell, but after 8 hours and 16 hours of Taxol treatment followed
by HU removal, the p-H3 positive population was 1.54% and 1.5% compare to
0.025% and 0.040% in NPRL2/TUSC4 deficient cells, similar results supported the
role of NPRL2/TUSC4 in replication stress recovery were described previously.
Together, these results suggested NPRL2/TUSC4 plays an important role in
maintain genomic stability and inhibit the proliferations of breast tumor cells both in
vitro and in vivo, and this function is dependent on NPRL2/TUSC4’s capacity to
stabilize tumor suppressor BRCA1 and regulate cell cycle checkpoint, HR repair
(Figure 33 A, B).
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Figure 28. NPRL2/TUSC4 plays an important role as a tumor suppressor in
breast cancer
A. NPRL2/TUSC4 overexpression in MDA-MB-231cells (stable clones
NPRL2/TUSC4 #7 and #13) significantly reduced the breast tumor growth in
nude mice (p<0.05) compared to control 231 cells, the relative tumor size were
indicated and compared as shown.
B. Tumor growth percentage of total injected mice by week after the injection of
the MDA-MB-231 cells as well as two NPRL2/TUSC4 overexpression cell lines
(#7 and #13).
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Figure 29. NPRL2/TUSC4 deficiency sensitized U2OS cells to PARP inhibitor
A. Colony formation assay indicated that normal U2OS cells are not sensitive to
PARP inhibitor Olaparib (1μm) but NPRL2/TUSC4-knockdown cells exhibited
increased sensitivity to Olaparib, the colonies were significantly reduced after the
treatment (p<0.05);
B. Colony formation assay indicated that normal U2OS cells are not sensitive to
PARP inhibitor Rucaparib (1μm) but NPRL2/TUSC4-knockdown cells exhibited
increased sensitivity to Rucaparib, the colonies were significantly reduced after the
treatment (p<0.05).
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Table 1. Tumorigenecity of MDA-MB231 cells with NPRL2/TUSC4
overexpression
5×106 cells from MDA-AB-231 control and two independent NPRL2/TUSC4overexpressing MDA-AB-231 cell lines (NPRL2/TUSC4 #7 and NPRL2/TUSC4
#13) were injected per mouse into mammary tumor sizes were analyzed.
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Table 2. Tumorigenecity of MCF10A cells with NPRL2/TUSC4 depletion
1×107 cells from MCF-10A control and two independent NPRL2/TUSC4knockdown MCF-10A cell lines (NPRL2/TUSC4 #1 and NPRL2/TUSC4 #4) were
injected per mouse into mammary fat pads glands of 6-week-old female nude mice.
Each cell line was injected in five different mice, and tumor sizes were analyzed.
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D.

Figure 30. Colony formation assay of NPRL2/TUSC4 overexpression and
NPRL2/TUSC4 knockdown cells
A. Colony formation of MDA-MB-231 cells, as well as 2 stable NPRL2/TUSC4
overexpression 231 cells (#7 and #13) before injection was displayed. B. Western
Blot confirmed the NPRL2/TUSC4 overexpression in 231 cells, including #7 and
#13. C. Colony formation of MCF-10A cells, as well as 2 stable 10A knockdown
cell lines (#1 and #4) before injection was displayed. D. Western Blot confirmed the
NPRL2/TUSC4 knockdown in 10A cells, including clone #1 and #4.
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Figure 31. NPRL2/TUSC4 knockdown reduced Rad51 protein foci after UV
NPRL2/TUSC4 knockdown reduced Rad51 foci formation after UV, while control
cells (NT) didn’t have such effect. BRCA1 indicated the efficiency of irradiation.
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Figure 32. NPRL2/TUSC4 depletion slowed down the cell cycle progression
under stress conditions
Control, NPRL2/TUSC4 knockdown and NPRL2/TUSC4 knockdown/reintroduction
cells were treated with HU for 24 hours, then HU were removed and Taxol were
added to arrest cells in G2 phase, 0 h, 8 h, 16 h after Taxol treatment were
collected for cell cycle analysis
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Figure 33. NPRL2/TUSC4 depletion is associated with reduced proliferation
rate
A. NPRL2/TUSC4 depleted cells showed significantly reduced p-H3 staining
compare to control cells after Taxol treatment in 8 hours and 16 hours;
B. Reintroduction of NPRL2/TUSC4 and CHK1 in NPRL2/TUSC4 depleted cells
rescued p-H3 staining compare to NPRL2/TUSC4 depleted cells alone. All cells
were treated with HU for 24 hours and Taxol for 8 or 16 hours.
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Chapter 5
DISCUSSION
DNA damage response is critical to maintain genomic integrity and it
safeguards the fidelity of genetic information to pass to the next generation of cells.
The deficiency of DNA damage response especially in the early stage increased
the incidence of cancer lesions. As one of the most important protein in DNA
damage response, BRCA1 mediates the error-free homologous recombination
repair and suppress the occurrence of early cancer lesions. Here we provided
evidence that tumor suppressor protein NPRL2/TUSC4 can stabilize the
expression levels of BRCA1 by preventing BRCA1's E3 ligase HERC2 from binding
it. Interestingly, inactivation of NPRL2/TUSC4 has also been shown to associate
with poor 5-year clinical survival rates in breast cancer patients, indicating
NPRL2/TUSC4 plays a role in inhibiting tumor growth and maintaining genome
integrity against the multiple types of stress.
BRCA1's recruitment to damage sites is considered one of the critical
events in HR repair. Inactivation of NPRL2/TUSC4 abolished the DNA damage foci
of BRCA1 under both IR and UV treatments, suggested the regulation BRCA1's
stability in DNA damage response may not only go through the process followed by
the CHK2 phosphorylation, due to the lack of kinase activity of NPRL2/TUSC4. In
fact, a previous report described that NPRL2/TUSC4 inhibits AKT pathway by
physically interacting with the upstream PDK1 protein, and it can block the
phosphorylation sites on PDK1 and prevents co-activator Src from binding. Thus,
it's not surprising that NPRL2/TUSC4's binding domain is responsible for multiple
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proteins' interaction and functions as tumor suppressor. Indeed, NPRL2/TUSC4
does bind to BRCA1's E3 ligase HERC2 but not with BRCA1 itself.
Our initial observation that NPRL2/TUSC4 can form damage foci after UV
and IR suggested that NPRL2/TUSC4's potential function in nuclear. This result
was confirmed by nuclear fractionation experiments showing that NPRL2/TUSC4 is
diversely expressed from cytoplasm to nuclear. Although it's not clear whether
NPRL2/TUSC4 co-localizes with BRCA1 after irradiation, we noticed that after
NPRL2/TUSC4 was knocked down, BRCA1 foci was significantly reduced. This
leads to two possibilities; either BRCA1's stability was impaired thus foci couldn't
be formed or the BRCA1's recruitment to damaged sites was blocked. Considering
BRCA1's important role in homologous recombination repair, we suspected that if
BRCA1's expression level is reduced, the HR repair efficiency would also get
affected. So, we used previously established U2OS cell systems to evaluate the
HR repair efficiency by the levels of released GFP. The graphs clearly show that
knockdown of NPRL2/TUSC4 has similar effects compared to BRCA1 knockdown
samples, which served as positive control. This results was consistent with our
hypothesis that inactivation of NPRL2/TUSC4 leads to the reduced expression
levels of BRCA1. More interestingly, after the analysis of Western blots, we also
identified that BRCA1's expression level was significantly reduced in the lane of
NPRL2/TUSC4 knockdown sample, indicating the NPRL2/TUSC4 inactivation
leads to the decreased stability of BRCA1 protein itself. These data support the
idea that reduced BRCA1 damage-induced foci is due to reduced BRCA1 stability.
However, we still can't rule out the possibility that NPRL2/TUSC4 inactivation also
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impairs the cell’s capacity to recruit BRCA1 to the foci sites. Furthermore, to
confirm that the defective HR repair efficiency was not caused by transfection
efficiency or inaccurate efficiency from I-SceI, we reintroduced BRCA1 plasmids
into the NPRL2/TUSC4-knockdown cells, and as expected, we observed a
significant increase in HR repair efficiency compare to that in NPRL2/TUSC4knockdown-only cells. The introduction of BRCA1 expression caused partial
restoration of HR repair efficiency, the main reason is that NPRL2/TUSC4 also
interacts with other DNA damage response and repair proteins involved in HR
repair (data not shown).
For a better understanding of the relationship between NPRL2/TUSC4 and
BRCA1, we first conducted microarray analysis by using the NPRL2/TUSC4 stable
U2OS cell lines with the appropriate controls. We then isolated the significantly
different genes with both up- and down-regulation and input into Ingenuity Pathway
Analysis (IPA) system for pathway enrichment analysis. The results indicated
NPRL2/TUSC4 knockdown leads to the critical pathway changes including cancer,
cell cycle, cell death, etc. This is consistent with the previous studies that
NPRL2/TUSC4 has been widely accepted as a tumor suppressor gene. Top
molecular pathways also indicated NPRL2/TUSC4 knockdown cells is associated
with role of BRCA1 in DNA damage response, which further supported our
statement that NPRL2/TUSC4 knockdown is negatively associated BRCA1's
function.
We previously established HR repair-deficiency gene signatures and
identified 230 genes that predict HR repair deficiency across tumor types. BRCA1
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deficiency had been utilized as one of the phenotypes to generate the signature.
We surprisingly identified similar HRD gene signature patterns in NPRL2/TUSC4and BRCA1-deficient cells, suggesting an association between these two proteins
and shedding light for the exploration of regulation networks for NPRL2/TUSC4
and BRCA1. To further validate this hypothesis, we also performed RPPA with
BRCA1 and NPRL2/TUSC4 deficient cells as well as control cells, at the protein
level, NPRL2/TUSC4 and BRCA1 knockdown exhibited similar protein expression
patterns in the clusters, indicating similar protein and pathway changes were
observed and this result is highly consistent with the microarray analysis at mRNA
level. Multiple research groups published that BRCA1-deficicency is correlated
with high sensitivity of tumor cells and animal models to PARP inhibitor. The
underlying mechanism is that inhibition of PARP1 will accumulate unrepaired single
strand break and ultimately leads to double strand break. Our data also showed the
TSUC4 deficient cells are more sensitive to the treatment of multiple PARP
inhibitors, which is consistent with the rationales of our work. It also suggested the
potential clinical usage of PARP inhibitors to treat NPRL2/TUSC4-defieicent breast
cancer.
To determine whether the regulation of BRCA1 by NPRL2/TUSC4 is caused
by the altered cell-cycle distribution because BRCA1 expression is known to be
cell-cycle regulated, we first performed cell cycle analysis and found no significant
difference between the normal U2OS cells and NPRL2/TUSC4 stable knockdown
cells. This ruled out the possibility the reduced BRCA1 expression level is due to
the different stages of cell cycle. To test whether BRCA1 is regulated by
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NPRL2/TUSC4 at the mRNA level, RT-PCR was performed. We observed that
BRCA1 mRNA levels had no significant differences between control cells and two
NPRL2/TUSC4 deficient cells. This result is also consistent with the previous
microarray analysis, which showed no changes at the BRCA1 mRNA level, even
clear molecular pathway changes were identified.
Another possibility could be that NPRL2/TUSC4 regulates BRCA1's
stability at the protein level. To determine if this hypothesis is true, we treated
control and NPRL2/TUSC4-knockdown U2OS cells with CHX, for the purpose of
blocking protein synthesis, and proteasome inhibitor MG132. Surprisingly, we
found that NPRL2/TUSC4 knockdown reduced the half-life of BRCA1 from about
20 h to less than 6 h. MG132-based treatment restored BRCA1 expression in cells
with NPRL2/TUSC4 knockdown but such phenotype was not observed in control
cells. These two results combined together suggested that NPRL2/TUSC4 plays an
essential role in stabilizing BRCA1 at the protein level and NPRL2/TUSC4
regulates BRCA1 protein stability via the proteasome-dependent pathway. Multiple
groups have reported HERC2 serves as the E3 ligase of BRCA1. To determine
whether NPRL2/TUSC4 regulates BRCA1 stability via HERC2, we performed
ubiquitination assay by transfecting (HA)-tagged ubiquitin plasmids into cells with
or without NPRL2/TUSC4 knockdown, followed by immunoprecipitation with control
IgG or an anti-BRCA1 antibody. After treatment with MG132, Western blotting for
HA-tagged ubiquitin showed that NPRL2/TUSC4-knockdown cells underwent
heavy ubiquitination, whereas control cells exhibited only a light polyubiquitination
ladder indicating that knockdown of NPRL2/TUSC4 expression caused a robust
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increase in BRCA1 protein polyubiquitination. We also confirmed that depletion the
expression of HERC2 led to increased expression of BRCA1 regardless of the
presence of NPRL2/TUSC4. These data further suggested the role of
NPRL2/TUSC4 in regulation of BRCA1 stability via ubiqutination pathway via
HERC2.
Thus, the next question to be answered was how NPRL2/TUSC4 affects the
ubiquitination of BRCA1 via HERC2. By performing immunoprecipitation, we found
that NPRL2/TUSC4 physically interacts with HERC2 but not with BRCA1, which
strongly suggested that NPRL2/TUSC4 regulates BRCA1 stability via interaction
with

HERC2.

Considering

the

previously

reported

binding

functions

of

NPRL2/TUSC4, we suspected that NPRL2/TUSC4 may prevent physical
interaction between BRCA1 and HERC2. The binding between these two proteins
has been previously described, so we performed further immunoprecipitation to
determine whether overexpression of NPRL2/TUSC4 weakens this binding.
Intriguingly, overexpression of NPRL2/TUSC4 interrupted the binding between
HERC2 and BRCA1, indicating that NPRL2/TUSC4 may regulate BRCA1 stability
by preventing physical interaction between BRCA1 and HERC2.
In the present study, we demonstrated for the first time that expression of
NPRL2/TUSC4 can positively regulate the stability of BRCA1 by preventing
physical interaction between BRCA1 and its identified E3 ligase HERC2, which in
turn protects BRCA1 from ubiquitination and degradation. Because NPRL2/TUSC4
knockdown is negatively correlated with BRCA1 protein expression and
considering the previously reported protein-binding and -blocking capacity of
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NPRL2/TUSC4 between PDK1 and its co-activator Src, we suspected that
NPRL2/TUSC4 plays a similar role in disrupting the interaction between BRCA1
and HERC2. Indeed, we found that NPRL2/TUSC4 physically interacts with
BRCA1’s E3 ligase HERC2 but not with BRCA1 itself. Overexpression of
NPRL2/TUSC4 markedly weakened their interaction in immunoprecipitation
experiments. This observation explained how NPRL2/TUSC4 overexpression can
protect BRCA1 from degradation and greatly reduce the proliferation of breast
cancer. Thus, the regulatory mechanisms of NPRL2/TUSC4 function in blocking
the AKT pathway and stabilizing BRCA1 protein expression may be similar.
NPRL2/TUSC4 does not have phosphorylation or E3 ligase activity according to
functional domain analysis, so we speculated that its potential functions in the DNA
damage response network and as a tumor suppressor are common mechanisms
by the physical interaction, stabilizing or preventing activation of target proteins.
Regardless of the effect of HERC2 on BRCA1, our data has demonstrated
that NPRL2/TUSC4 inactivation significantly impaired the stability of BRCA1, and
in turn negatively regulate the efficiency of HR repair and cells' capacity to
response to PRAP inhibitor. We demonstrated further that the reduced stability of
BRCA1 is owing to its E3 ligase HERC2 binding, and NPRL2/TUSC4 can
physically interact with HERC2 and weaken the binding between BRCA1 and
HERC2. When NPRL2/TUSC4 is inactivated, HERC2 is able to reform the binding
complex with BRCA1 and thus decrease BRCA1's expression via protein
degradation

pathway.

Our

data

strongly

NPRL2/TUSC4 regulates BRCA1's stability.
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supported

our

hypothesis

that

BRCA1 expression level was reported to be negatively regulated by
apoptosis pathway under the condition of UV. More specifically, BRCA1 is cleaved
by caspase-3 after UV treatment, while mutated BRCA1 with non-cleavable
capacity can negatively regulate cell death and block GADD5/JNK signaling (Zhan
et al., 2002). Although BRCA1 plays an important role in DNA damage response
and repair, the mechanism of when BRCA1 participates into the DNA double
strand break response is still largely unknown. Thus, to understand the
physiological condition of when BRCA1 is regulated will promote our understanding
when and why the regulation between NPRL2/TUSC4 and BRCA1 take place. In
fact, our data (not shown) also indicated that NPRL2/TUSC4 knockdown altered
the cell cycle distributions of U2OS cells compare to ATM or ATR knockdown, after
IR treatments. Considering BRCA1 is cell cycle dependent, this result suggested
the regulation of BRCA1 by NPRL2/TUSC4 may not only happen under normal
conditions, but also play roles under the conditions of IR. However, further
research need to be performed to confirm this hypothesis.
Upon DNA damage, BRCA1 was previously reported to aggregate and colocalize with γ-H2AX to the nuclear foci (Paull et al., 2000). Multiple factors can
affect BRCA1's foci formation including UBC13/RNF8 ligase in ubiquitination
pathway (Wang and Elledge, 2007). In our current study, although the knockdown
of NPRL2/TUSC4 reduced the stability of BRCA1, but whether the reduced BRCA1
foci formation was owing to the reduced BRCA1 expression is still unknown.
Considering the fact that NPRL2/TUSC4 regulates BRCA1's stability via the
ubiquitination pathway, it's also likely that NPRL2/TUSC4 also involves the
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BRCA1's recruitment to the foci. This hypothesis can be tested by checking if
NPRL2/TUSC4 co-localize with BRCA1 after irradiation.
Another function of NPRL2/TUSC4 was reported in 2013 (Bar-Peled, 2013),
explaining that NPRL2/TUSC4 forms complex with NPRL3 and DEPDC5 to
negatively regulate mTORC1 pathway. Inactivation of this complex will lead
hyperactive cell growth, due to the insensitivity to amino acid deprivation, and
hypersensitive to mTORC1 target drug rapamycin. Because Gag guanosine
triphosphatases (GTPases) involves in the translocation of mTORC1 to lysosomal
surface, and the complex mentioned above suppress the GTPases activity, this
result suggested that NPRL2/TUSC4’s potential function in promoting or
suppressing the protein trafficking, and might shuttle proteins among different
cellular apparatuses. In fact, nuclear transport of BCRA1from cytoplasm to the
nucleus by NLS receptor mediated system has been previously described (Chen et
al, 1996). Therefore, the regulation location between NPRL2/TUSC4 and BRCA1
needs to be further investigated. Additionally, the difference between normal
conditions and under irradiation will also need to be compared. In other words,
upon the DNA damage response, will BRCA1 be shuttled from cytoplasm to
nucleus, and whether NPRL2/TUSC4 stabilizes BRCA1 in nucleus? If this is true,
the recruitment of NPRL2/TUSC4 to DNA damage foci will occur with BRCA1’s
transport simultaneously, even NPRL2/TUSC4 doesn’t physically interact with
BRCA1. In this case, future work still need to be done to identify the mechanism
behind NPRL2/TUSC4 also positively regulates BRCA1’s stability at normal
physical conditions, is there any feedback loop involves in this negative regulation
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of BRCA1 expression to maintain the minimal BRCA1 expression level
(Baldassarre G et al, 2003; Mueller CR and Roskelley CD, 2003).
Other than HR repair, BCRA1 was also reported to associate with KU80
during NHEJ repair to maintain the fidelity end-joining and maintain the repair
efficiency (Jiang et al, 2013). However, the regulation only happens in certain types
of NHEJ (in-vivo precise NHEJ), thus, even NPRL2/TUSC4 might play roles in
regulating NHEJ repair, such functions are most likely to limited into the framework
of BRCA1 stability based on our current understanding. However, further research
can be performed to identify if NPRL2/TUSC4 affect the activities of critical NHEJ
repair effectors such as KU70-KU80 dimers and 53BP1.

Clinical relevance of NPRL2/TUSC4 regulation of BRCA1
We have identified NPRL2/TUSC4 functions as tumor suppressor gene in
breast cancer, possibly through positively regulating BRCA1. Next, we postulated
that overexpression of NPRL2/TUSC4 also suppresses breast tumor proliferation in
vitro and in vivo. To validate this, we compared the proliferation rate of the breast
cancer cell line MDA-MB-231 with or without NPRL2/TUSC4 overexpression.
Colony formation assays indicated markedly reduced proliferation of the
NPRL2/TUSC4-overexpressing cells (Figure 30A). Because NPRL2/TUSC4
effectively inhibits breast cancer cell growth in vitro, we further examined the effect
of NPRL2/TUSC4 overexpression in a xenograft mouse model of breast cancer.
We injected female mice with control or NPRL2/TUSC4-overexpressing MDA-MB-
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231cells into the mammary fatpads. We then monitored and measured tumor
growth weekly. By week 6 after injection, 5 of 10 mice injected with
NPRL2/TUSC4-overexpressing cells remained tumor-free, whereas all 5 mice
injected with control 231 cells had large tumors (Figure 28 A, B; Table 1).
Previous reports indicated that HR repair defect sensitizes cancer cells to
DNA damaging drug (Foray et al 1999; Deng and Wang 2003) and the poly(ADPribose) polymerase (PARP) inhibitor (Alli et al., 2009; Powell and Kachnic, 2003).
Thus, NPRL2/TUSC4 deficiency cells with HR repair defect are highly likely to be
more sensitive to the treatment of PARP inhibitor, which can effectively inhibit the
repair of single strand DNA break. To confirm this hypothesis, we performed colony
formation assay in U2OS cell with NPRL2/TUSC4 knockdown after PARP inhibitor
Olaparib and Rucaparib treatment, as well as control cells. As we expected, both
drug significantly reduced the colony formation in NPRL2/TUSC4 knockdown cells
compared the control cells (Figure 29 A,B). Additionally, we examined
NPRL2/TUSC4

depletion

to determine whether it initiates breast

tumor

development in a xenograft mouse model. We injected MCF-10A cells with stable
knockdown of NPRL2/TUSC4 expression and the control cells into the mammary
fatpads of female nude mice. Similar to the procedure described above, we closely
monitored tumor formation in the mice. Notably, tumors began to form in 3 of 10
mice injected with NPRL2/TUSC4-knockdown cells after 3 weeks, whereas no
tumors formed in the control groups (Table 2). These results demonstrated that
loss of NPRL2/TUSC4 expression alone is sufficient to initiate malignant
transformation of immortalized nontransformed mammary epithelial cells, which is
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consistent with our hypothesis that NPRL2/TUSC4 functions as a bona fide tumor
suppressor in breast cancer.
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Chapter 6
FUTURE WORK
Further explore the interaction between NPRL2/TUSC4 and HERC2
We have successfully identified that NPRL2/TUSC4 physically interacts with
E3 ligase HERC2 but not BRCA1, thus blocking the binding between HERC2 and
BRCA1, in turn stabilizing BRCA1's expression and maintaining its functions in HR
repair

and

other

DNA

damage

responses.

Previous

report

indicated

NPRL2/TUSC4's N-terminal 133 amino acid residues are responsible for the
binding of NPRL2/TUSC4 to PDK1's phosphorylation sites (Kurata et al., 2008).
Also, HERC2's C-terminal HECT domain is responsible for the binding of BRCA1's
N-terminal degron domain (Wu et al, 2010). The unanswered question is whether
NPRL2/TUSC4's N-terminal domain is also responsible for the binding of HERC2,
and if so, is HERC2's C-terminal domain involved in the binding. We have
generated deletion mutations of NPRL2/TUSC4-FLAG stable clones to test this
hypothesis. If the results show that NPRL2/TUSC4's N-terminus physically interact
with HERC2's c-terminus, it will not only confirm the functions of both
NPRL2/TUSC4 and HERC2 's binding domain, but it will also provide clinical
insights to target binding domains of HERC2 to treat BRCA1down-regulation
patients in multiple types of cancers (Moskwa et al, 2010; Deutsch et al.,2003;
Beger et al., 2004). Furthermore, it has been also shown BARD1 protects BRCA1
from HERC2-mediated ubiquitination and HERC2 degrades BRCA1 regardless of
the existence of BARD1 (Wu et al., 2010). as an extensively studies BRCA1-Ring
domain binding protein, if NPRL2/TUSC4 knockdown affect BARD1's binding with
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BRCA1, if so, does this disassociation allow BRCA1's RING domain becomes
more accessible for HERC2’s targeting? An alternative model could be
NPRL2/TUSC4 binds HERC2 and BARD1 (instead of BRCA1) to realize its
function in mediating BRCA1's stability. Together these experiments could provide
evidence to support our current model or to help establish revised model of
NPRL2/TUSC4's function in BRCA1 and HERC2 interaction (Figure 23, 24).

Determine the function of NPRL2/TUSC4 in replication stress response
Besides the data shown in this dissertation, we have also discovered the
association of NPRL2/TUSC4 in replication stress response. NPRL2/TUSC4
exhibited extensive binding capacity to proteins other than PDK1 and HERC2, as
mentioned previously. Other major DNA damage response kinase such as ATM
and ATR also physically interact with NPRL2/TSUC4. This would explain our
observation in the HR repair assay that double knockdown of TSUC4 and BRCA1
further reduced the reporter protein GFP's level, and overexpression of BRCA1 in
the cells with NPRL2/TUSC4 knockdown didn't completely restore the HR repair
efficiency. If BRCA1 is not the only downstream targets of NPRL2/TUSC4
inactivation, the phenomenon we observed matched the hypothesis that
NPRL2/TUSC4 play a more intensive role in DNA damage response network.
Although NPRL2/TUSC4 knockdown cells shows no significant difference of cell
cycles distribution compare to control, after both cells were treated with
Hydroxyurea (HU), NPRL2/TUSC4-deficient cells exhibited extended G1 arrest
while controls cells were able to escape from G1 arrest. This data suggested

- 97 -

NPRL2/TUSC4's function in mediating cell cycle checkpoints, which is consistent
with our previous IPA analysis, which indicated that NPRL2/TUSC4 knockdown
globally changed the gene expression profiles of cell cycle checkpoint regulation
and DNA damage responses. The mechanisms under this regulation needs to be
explored to test if these bindings are also regulated by the ubiquitination pathway.
Based on the recent findings that NPRL2/TUSC4 mRNA levels are significantly
reduced with the progression of cancer development, and low NPRL2/TUSC4 level
correlates with multiple drugs' resistance so it is worth taking the possibility into
consideration in which decreased NPRL2/TUSC4 expression levels are associated
with the stability or functions of these major DNA damage response kinase.
Understanding of the mechanism whereby NPRL2/TUSC4 negatively regulates
these kinases is significant because of the effect it has on replication stress
response and potential application in clinical drug design or selection. Most likely,
these regulation will process through the binding or blocking due to the lack of
functional domains of NPRL2/TUSC4 such as phosphoryation, so the direct
regulation of NPRL2/TUSC4 to these kinase is not likely. But considering, the
conserved SQ/TQ motif in NPRL2/TUSC4 sequences cross the species, it's highly
possible NPRL2/TUSC4 can also serve as the binding substrates of ATM/ATR
protein, and regulate their activities.

Further demonstrate NPRL2/TUSC4-deficient cells' drug sensitivity
We have

identified

the

increased

sensitivity of

U2OS

cells

with

NPRL2/TUSC4-deficiency, largely due to decreased BRCA1 stability and impaired
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HR repair capacity by the cells. The signatures involves in HR repair deficiency has
been established by our previous work (Peng et al., 2014). Although
NPRL2/TUSC4 KD can also clearly form a cluster pattern based on the 230
identified gene signatures, it will be interesting to evaluate the changes in more
details. For example, HR repair proteins other than BRCA1 could also be involved
after NPRL2/TUSC4's expression is reduced. It's logical that these gene changes
in NPRL2/TUSC4 deficient cells overlaps BRCA1 deficiency (and PTEN deficiency)
gene signatures which the signature established from, it actually narrowed down
the numbers of genes potentially involves in the pathways followed by
NPRL2/TUSC4 inactivation. Additionally, NPRL2/TUSC4's low expression has also
been identified as the cause of CPT resistance in lung cancer. The proposed
mechanism is that NPRL2/TUSC4 deficiency failed to stabilize the DNA damage
response signaling cascades (Jayachandran et al., 2010). It's still unclear what
other proteins associated with drug responses after NPRL2/TUSC4's inactivation
and it would be interesting to map out the pathways affected by NPRL2/TUSC4's
deficiency, and to determine if BRCA1 is the only readout which affected the
sensitivity of drug treatment such as PARP inhibitors and DNA damaging reagents.
Annexin V staining can also be conducted to investigate if NPRL2/TUSC4
knockdown leads to the increase of apoptosis cell populations before and after
treatment with different drugs. We propose that depending on the drugs'
mechanism and target, the results will not provide same effect of TSUC4 deficiency
cells, it also needs to take the cell or cancer types into consideration.
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Further investigate NPRL2/TUSC4's role as a tumor suppressor
We and others provide evidence that both NPRL2/TUSC4 overexpression
in vitro and in vivo inhibited breast cancer cell proliferation and tumor development.
The same effect of NPRL2/TUSC4 was identified in non-small cell lung cancer (Li
et al., 2004). Moreover, we showed for the first time that depletion of
NPRL2/TUSC4 in non-transformed 10A cell lines promoted the genomic instability
and lead to the occurrence of early breast cancer lesions in nude mice models. To
further confirm this hypothesis, additional experiments are necessary to include
into the future work. For example, comet assay can be done to determine the
genomic instability after NPRL2/TUSC4 knockdown and invasion assay can be
done to explore if NPRL2/TUSC4 deficiency increases cell's malignancy and
mobility.
In

our

in

vivo

experiments,

we

injected

MDA-MB-231

cells

with

NPRL2/TUSC4-flag overexpression into nude mice and observed much slower
tumor growth rates compared to normal MDA-MB-231 cells. MDA-MB-231 cells are
categorized as basal breast cancer cell lines, which share common characteristics
as triple negative breast cancer types (Badev et al., 2011). We identified that
NPRL2/TUSC4 knockdown cells exhibit a more basal-like gene expression profiles
than luminal. This indicates that NPRL2/TUSC4 can serve as a biomarker to treat
basal-like or triple negative breast cancer, or the marker to indicate therapy
efficiency.

Drug screening will also be extremely useful to distinguish if

NPRL2/TUSC4 can be used as marker for that purpose. Together, these

- 100 -

experiments will lead us to a better understanding of the roles of NPRL2/TUSC4 as
tumor suppressor.
Finally, since NPRL2/TUSC4 expression levels vary depending on organs
and tissues, it would be interesting to investigate whether this protein functions only
in maintaining genome stability, and whether its function across various cancers is
tissue-specific.
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